ASHBURN, Va., April 17, 2013 /PRNewswire/ -- Innocoll, Inc. announced it has entered into an exclusive License and Distribution Agreement with Biomet 3i for its range of CollaCare Dental products. This agreement covers all global territories outside of China and ASEAN, which have been previously partnered.
The CollaCare products were developed using Innocoll's proprietary collagen based technologies. The products are comprised of a lyophilized matrix of purified type I collagen available in a variety of easy-to-apply formats including sponge, tape, cone, and powder. The products are indicated for topical hemostasis and/or the management to clean oral wounds such as dental and periodontal surgical wounds, extraction sites, traumatic oral wounds, denture sores, oral ulcers, and burns. Because the products are composed of native fibrillar collagen, Collacare Dental has intrinsic haemostatic properties such that topical administration directly over the wound effectively controls bleeding, usually within approximately three minutes. The highly porous structure also enables absorption of fluids and upon hydration the dressings are conformable to the shape of the wound. Collacare Dental may also serve as temporary wound dressings during prolonged dental procedures. CollaCare dental products are currently approved for sale in the United States and Europe.
Dr. Michael Myers, President and CEO of Innocoll stated, "With the execution of this agreement between Biomet 3i, Innocoll has now secured global distribution for our CollaCare Dental range. This is another significant step for Innocoll as we expand the reach of our product portfolio and further demonstrates the broad applicability of our technology in a diverse range of surgical and wound healing settings."
About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil, CollaPressTM and Liquicoll®.
Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Zorpreva, and LidoColl®.
Products in clinical and regulatory development include: Cogenzia® in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, XaraColl® in phase 3 development for the management of post-operative pain and Durieva, a dura on-lay/ dura replacement product. For more information, please visit www.innocollinc.com.
SOURCE Innocoll, Inc.